Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation
- Conditions
- Stress, Psychological
- Interventions
- Biological: Blood collectionDevice: PhotoplethysmographyBehavioral: Psychological questionnairesDrug: Placebo
- Registration Number
- NCT04549194
- Lead Sponsor
- Direction Centrale du Service de Santé des Armées
- Brief Summary
Operational conditions amplify soldier's constraints and stress factors, upsetting individual and collective adaptive landmarks. The soldier's resistance is strained by the high intensity of stressors, by the long duration of exposure and by their cumulative effect.
This may lead to a state of "operational strain" that refers to chronic stress and the allostatic load imposed by operational constraint.
The investigators believe that operational strain could manifest itself by a kind of accelerated aging of the organism due to the increased allostatic load without sufficient resource restoration (neurotransmitter precursors, partial and repeated sleep deprivation, etc.).
This aging mechanism would be reversible after a sufficient period of resource restoration (sleep, physical activity, adapted diet, etc.).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 116
- From 18 to 65 years of age
- Tyrosine intake within the previous 15 days
- History of neurological or psychiatric disorder
- History of nephrological or endocrine disorder or liver failure
- Hereditary tyrosinemia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tyrosine - Rear Base L-Tyrosine 500 Mg 1-month L-Tyrosine treatment following 4 months at rear base Placebo - External Operation Photoplethysmography 1-month Placebo treatment following 4-month external operation Tyrosine - External Operation Blood collection 1-month L-Tyrosine treatment following 4-month external operation Tyrosine - External Operation Photoplethysmography 1-month L-Tyrosine treatment following 4-month external operation Placebo - Rear Base Blood collection 1-month Placebo treatment following 4 months at rear base Tyrosine - External Operation L-Tyrosine 500 Mg 1-month L-Tyrosine treatment following 4-month external operation Tyrosine - External Operation Psychological questionnaires 1-month L-Tyrosine treatment following 4-month external operation Placebo - External Operation Psychological questionnaires 1-month Placebo treatment following 4-month external operation Placebo - External Operation Placebo 1-month Placebo treatment following 4-month external operation Tyrosine - Rear Base Psychological questionnaires 1-month L-Tyrosine treatment following 4 months at rear base Placebo - External Operation Blood collection 1-month Placebo treatment following 4-month external operation Tyrosine - Rear Base Blood collection 1-month L-Tyrosine treatment following 4 months at rear base Tyrosine - Rear Base Photoplethysmography 1-month L-Tyrosine treatment following 4 months at rear base Placebo - Rear Base Psychological questionnaires 1-month Placebo treatment following 4 months at rear base Placebo - Rear Base Photoplethysmography 1-month Placebo treatment following 4 months at rear base Placebo - Rear Base Placebo 1-month Placebo treatment following 4 months at rear base
- Primary Outcome Measures
Name Time Method Difference between the change in Burnout Assessment Tool (BAT) score following 1-month treatment in each arm After 1-month treatment The Burnout Assessment Tool (BAT) is used to assess burn-out risk. The score ranges from 1 to 5, with higher scores indicating a higher risk of burn-out.
- Secondary Outcome Measures
Name Time Method Difference between the change in catecholamine level following 1-month treatment in each arm After 1-month treatment Catecholamine level will be measured in blood before during and after 1-month treatment.
Difference between the change in zonulin level following 1-month treatment in each arm After 1-month treatment Zonulin level will be measured in blood before during and after 1-month treatment.
Difference between the change in Interleukin-6 (IL6) level following 1-month treatment in each arm After 1-month treatment IL6 level will be measured in blood before during and after 1-month treatment.
Difference between the change in Brain-Derived Neurotrophic Factor (BDNF) level following 1-month treatment in each arm After 1-month treatment BDNF level will be measured in blood before during and after 1-month treatment.
Difference between the change in Tumor Necrosis Factor Alpha (TNFα) level following 1-month treatment in each arm After 1-month treatment TNFα level will be measured in blood before during and after 1-month treatment.
Difference between the change in aminoacid level following 1-month treatment in each arm After 1-month treatment Aminoacid level will be measured in blood before during and after 1-month treatment.
Difference between the change in gamma-aminobutyric acid (GABA) level following 1-month treatment in each arm After 1-month treatment GABA level will be measured in blood before during and after 1-month treatment.
Trial Locations
- Locations (1)
Institut de Recherche Biomédicale des Armées
🇫🇷Brétigny-sur-Orge, France